Brasco Group Invest 8 Million Euro in Charles Real Estate Joint Venture Deal
22.2.2023 20:34:00 EET | Business Wire | Press release
The Brasco B.V. conglomerate is establishing a joint venture with the real estate company Charles Real Estate.
The Dutch company is thus consolidating its position in the German residential and commercial real estate market.
The Brasco Group continues on its investment tour: with its strategic investment in the joint venture with Charles Real Estate, the Dutch conglomerate is further diversifying its portfolio.
As a first step, the Brasco Group is investing EUR 8 million in the joint venture, and in the course of 2023 is planning to invest a further EUR 30 million.
Charles Real Estate, based in Berlin, has a portfolio of 550 units in Germany with a total lettable space of more than 33,000 square metres. The company's portfolio also includes a property currently under construction with a gross floor area of 16,000 square metres.
Industry insiders regard the investment as proof of the German real estate market's stability. As the coronavirus pandemic appears to have been largely overcome and the energy crisis has been less severe than initially feared, analysts see further growth potential in the German real estate market.
This is already the second investment by the Dutch group to attract attention this year: at the beginning of February, the company announced that it was investing in Mood's Clinic, a well-known manufacturer of medical cannabis.
The Brasco Group is a Dutch conglomerate and parent company of the Brasco group of companies. The Group specialises in trade and logistics, real estate development, financial services – in particular private equity – and the distribution of textiles. The main task of the parent company is to define the strategic orientation of the individual spheres of business and to promote their growth as well as the use of synergies through investment and communication.
The Dutch conglomerate relies on innovative trade concepts to remain competitive in the global and fast-moving circulation of goods and services.
The Group's core competence in the real estate sector is the purchase and management of existing high-end properties in sought-after locations within the Federal Republic of Germany.
The Brasco Group's finance division is responsible for managing and controlling the finances of subsidiaries, suppliers, partners, shareholders and investors. Only employees of the Brasco group of companies are authorised to manage finances, which ensures finances are managed securely.
The investment division of the conglomerate plays a central role in the acquisition of majority stakes: in recent decades, the company has advised on half of all global buyouts with a sales volume of more than $500 million. In addition to buy-out funds, the Brasco Group advises on other types of fund, including hedge funds, real estate funds, private equity funds and infrastructure funds. The Dutch company also advises pension fund, sovereign wealth fund and foundation managers.
More than 1,000 investment experts are associated with the company, and they accompany the investment cycle from the contract negotiation stage to planning the withdrawal.
The Brasco Group intends to float itself on the stock market at the end of 2024.
The Managing Director of the Brasco Group is Rafy Ahmed.
Rafy Ahmed is known to the public from the TV show "Lion's Den". Ahmed founded the fashion brand "Morotai" in 2017 which specialises in sportswear. In 2018, he was awarded the Founder's Prize of the State of Baden-Württemberg. In addition to his work as CEO, he is a lecturer at the International School of Management (ISM) in Stuttgart. As a successful young entrepreneur, he shows students how to start their career. The ISM Stuttgart intends to make the course he teaches an integral part of the "Global Brand & Fashion Management" degree course.
|
Language: |
English |
|
Company: |
Brasco Group |
|
Rivium Boulevard 301 beganegrond en 1e etage |
|
|
2909LK Capelle aan den IJsse |
|
|
Netherlands |
|
|
Internet: |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005788/en/
Contact information
Name: Rafy Ahmed
Tel: +905337840707
Email: info@brascogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom